|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-03
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
DACH1/Eya Cell fate determination factor and mammary tumorigenesis
|
5R01CA132115-09
|
$428,056
|
PESTELL, RICHARD
|
BARUCH S. BLUMBERG INSTITUTE
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
5R01CA207086-02
|
$370,641
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
5R01CA204926-02
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
The ATM/E2F1 Pathway in DNA Damage and Growth Control
|
5R01CA100857-14
|
$356,625
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder Cancer
|
5R01CA220297-02
|
$365,246
|
PUTLURI, NAGIREDDY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Tumor Suppressor Localization and Function at the Peroxisome
|
5R01CA143811-10
|
$356,625
|
WALKER, CHERYL
|
BAYLOR COLLEGE OF MEDICINE
|
|
NCOA6, A Novel Tumor Suppressor of Endometrial Cancer
|
5R01CA193455-03
|
$86,504
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
5R00CA197498-05
|
$249,000
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
5R01CA132755-11
|
$382,500
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Functional analysis of BRCA1 in DNA damage response and tumor suppression
|
5R01CA187209-05
|
$352,750
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Unmet needs for specific subsets of EGFR mutated lung cancer
|
1R37CA218707-01A1
|
$409,171
|
COSTA, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Tissue-specific genetic interactions in cancer
|
1R01CA232372-01
|
$505,643
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Basic and Translational studies of Ras-mutant colorectal cancer
|
5R01CA178017-05
|
$359,556
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Modeling KRAS genetic heterogeneity in mouse models
|
5R01CA195744-03
|
$635,205
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
5U01CA199252-04
|
$1,041,188
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressive Pathways for Cancer Therapy
|
5R35CA197529-04
|
$1,044,000
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Analysis of BRCA1 Recombination Functions
|
5R01CA095175-14
|
$328,700
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
FANCM in repair of stalled replication forks
|
5R01CA217991-02
|
$395,738
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
|
5R01CA200671-03
|
$395,738
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
5R01CA200573-03
|
$395,738
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
c-Met-induced Renalase: a novel therapeutic target for renal cancer
|
1R03CA219731-01A1
|
$88,500
|
BALAN, MURUGABASKAR
|
BOSTON CHILDREN'S HOSPITAL
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
5R01CA211328-02
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
p190 RhoGAP signaling in epithelial oncogenesis
|
5R01CA205158-02
|
$404,888
|
HANSEN, STEEN
|
BOSTON CHILDREN'S HOSPITAL
|
|
Role of Insulin Receptor Substrates in Kras-driven lung cancer
|
5R01CA211944-02
|
$404,888
|
KALAANY, NADA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
|
5R01CA193675-03
|
$404,888
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Role of c-Cbl in Colon cancer
|
5R01CA175382-05
|
$361,050
|
CHITALIA, VIPUL
|
BOSTON MEDICAL CENTER
|
|
Defining Novel Mechanisms of Genome Instability in BRAF-mutant Melanoma
|
1F30CA228388-01
|
$49,524
|
VITTORIA, MARC
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Elucidating the Regulation and Function of the NF1 tumor suppressor
|
5R01CA111754-13
|
$316,635
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Elucidating the role of new RasGAP tumor suppressors in cancer
|
5R01CA188659-05
|
$332,291
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Admin supplement - Chemical Approaches to Cell Signaling Enzymes
|
3R01CA074305-24S1
|
$73,513
|
COLE, PHILIP
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Chemical Approaches to Cell Signaling Enzymes
|
5R01CA074305-24
|
$340,100
|
COLE, PHILIP
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field
|
1R01CA222560-01
|
$374,766
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
De-Regulation of 5hmC/TET2 Tumor Suppressor under Anti-Estrogen Therapy
|
5R01CA194302-03
|
$405,036
|
SHI, YUJIANG
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas
|
5R01CA219943-02
|
$507,552
|
BEROUKHIM, RAMEEN
|
BROAD INSTITUTE, INC.
|
|
Systematic identification of oncogenic KRAS synthetic lethal interactions
|
5U01CA199253-04
|
$807,776
|
HAHN, WILLIAM
|
BROAD INSTITUTE, INC.
|
|
Epigenetic Regulation of Lipid Metabolism in Glioma Stem Cells
|
5F30CA217065-03
|
$44,524
|
GIMPLE, RYAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
FAM83B-mediated activation of EGFR signaling
|
5R01CA138421-08
|
$338,794
|
JACKSON, MARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Overcoming resistance to first generation small molecule activators of PP2A.
|
1F30CA224977-01
|
$44,524
|
LEONARD, DANIEL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
3R01CA177069-05S1
|
$75,000
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining the role of endometrial cancer PP2A A-alpha mutations in tumorigenesis
|
1F30CA224979-01A1
|
$44,524
|
TAYLOR, SARAH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutations
|
5R01CA196643-03
|
$383,725
|
WANG, ZHENGHE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-03
|
$418,127
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Investigation and functional characterization of new drivers of mesenchymal tumorigenesis.
|
4R00CA212200-03
|
$249,000
|
GUARNERIO, JLENIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
3R01CA143971-08S1
|
$149,644
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
7R01CA143971-08
|
$481,438
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma
|
1K08CA230223-01
|
$202,195
|
BOSSE, KRISTOPHER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|